Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment  by Santana, Marlon G. Veloso de et al.
Improved genetic stability of recombinant yellow fever 17D virus
expressing a lentiviral Gag gene fragment
Marlon G. Veloso de Santana a,c,1, Patrícia C.C. Neves a,1, Juliana Ribeiro dos Santos a,
Noemia S. Lima a, Alexandre A.C. dos Santos a, David I. Watkins c,
Ricardo Galler b, Myrna C. Bonaldo a,n
a Laboratório de Biologia Molecular de Flavivírus, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil
b Instituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
c Department of Pathology, University of Miami, Miller School of Medicine, United States of America
a r t i c l e i n f o
Article history:
Received 14 October 2013
Returned to author for revisions
11 November 2013
Accepted 20 January 2014
Available online 8 February 2014
Keywords:
Yellow Fever 17D virus
Viral vector
Genetic stability
SIV gag IRES
SIV Gag
Recombinant virus
a b s t r a c t
We have previously designed a method to construct viable recombinant Yellow Fever (YF) 17D viruses
expressing heterologous polypeptides including part of the Simian Immunodeﬁciency Virus (SIV) Gag
protein. However, the expressed region, encompassing amino acid residues from 45 to 269, was
genetically unstable. In this study, we improved the genetic stability of this recombinant YF 17D virus
by introducing mutations in the IRES element localized at the 50 end of the SIV gag gene. The new stable
recombinant virus elicited adaptive immune responses similar to those induced by the original
recombinant virus. It is, therefore, possible to increase recombinant stability by removing functional
motifs from the insert that may have deleterious effects on recombinant YF viral ﬁtness.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Yellow Fever (YF) 17D is one of the most effective vaccines
currently available. It was developed by Max Theiler and associ-
ates, who attenuated wild type strain Asibi by serial passages in
animal tissues. This vaccine has been used for 75 years in more
than 540 million people with an outstanding record of efﬁcacy and
safety. A single subcutaneous injection confers protection for at
least 10 years (Ciczora et al., 2010; Monath, 2004). The basis of this
strong and durable immune response is currently being investi-
gated. It is known that this vaccine virus activates different
pathways of the innate immune response, which lead to a
polyvalent adaptive response. Vaccination induces cytotoxic
CD8þ T memory cells, neutralizing antibody production and a
mixed TH1/TH2 response (Barba-Spaeth et al., 2005; Miller et al.,
2005; Querec et al., 2006; Santos et al., 2008).
These exceptional properties of the attenuated YF 17D vaccine
have led to the idea that this virus could be used as a vector for the
generation of new human vaccines (Bonaldo et al., 2000; Pugachev
et al., 2005). The YF virus is the prototype member of the genus
Flavivirus, which contains a positive strand RNA genome of about
11 kb (Chambers et al., 1990). Recombinant virus recovery is
possible by modifying the complete cDNA infectious clone of the
YF 17D vaccine virus, in vitro transcription and transfection of
infectious RNA molecules.
So far, several strategies have been developed to insert gene
sequences encoding microbial antigens in the YF genome. In some
of these approaches, short sequences that encode epitopes were
inserted into different genomic regions (Barba-Spaeth et al., 2005;
Bonaldo et al., 2002, 2005; McAllister et al., 2000; Tao et al., 2005).
However, a major concern in the development of recombinant YF 17D
vaccines relates to the limited size of the insert, because, unfortu-
nately, inserts longer than 40 codons do not generally produce
genetically stable viruses. The expression of larger fragments would
be desirable to promote a broader immune response. Hence, we have
developed a methodology to construct viable and immunogenic
recombinant YF 17D viruses that used the presence of functional
motifs and amino acid sequence conservation ﬂanking the E and
NS1 intergenic region. Duplication of these sequences and fusion to
the exogenous gene facilitated the correct processing of the viral
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polyprotein precursor (Bonaldo et al., 2007). Using this strategy, we
recovered a viable and immunogenic recombinant YF 17D virus
expressing a fragment of the SIV Gag protein (residues 45–269),
which elicited SIV-speciﬁc CD8þ T cell responses after immunization
of rhesus macaques (Bonaldo et al., 2010). However, this recombinant
virus was not stable, resulting in insert loss after serial passages in
Vero cell culture. Interestingly, this gag 45–269 minigene contains
part of a lentiviral IRES motif (Weill et al., 2010). We hypothesized
that the IRES motif might cause a substantial reduction in viral ﬁtness
leading to the positive selection of recombinant viruses in which the
gag gene insert has been partially deleted. To explore this hypothesis
and create new approaches to overcome this limitation, we con-
structed a variant recombinant YF 17D virus in which the IRES
element was knocked out. The resulting mutant virus retained the
foreign cassette for higher numbers of passages when compared to
the original recombinant YF17D/SIV Gag45–269 virus. It also retained
its biological and immunological properties, providing the basis for
further development of this platform for expressing relevant SIV/HIV
antigens and the development of new HIV vaccine candidates.
Results and discussion
Design of SIV gag minigene expression cassettes and recombinant
YF 17D virus recovery
We have previously described a strategy for the insertion and
expression of the heterologous sequences in the YF genomic E/NS1
intergenic region (Bonaldo et al., 2007). The rationale for this
approach was based on the fact that this insertion site represents a
functional shift from the structural to non-structural ﬂavivirus
genes accommodating larger inserts better than any other site in
the YF 17D virus genome. In our ﬁrst attempt to establish the use
of the YF 17D virus as a vector to express lentiviral antigens, we
inserted the SIV gag 45–269 gene region at the YF 17D E-NS1 site
(SIVmac239 gag gene position: 133–807; GenBank, AY588945).
This SIV gene region corresponds to the last 273 nucleotides of
the p17 Matrix protein gene (coding for 91 amino acid residues of
the carboxyl-terminus of the Matrix protein) and 402 nucleotides
of the 50 end of the Capsid gene (p24) encoding its ﬁrst 134 amino
acids.
The choice of this SIV antigen was based on the presence of a
well-characterized SIVmac239 CD8þ T cell epitope recognized by
rhesus monkey T cells (Allen et al., 2001). Recombinant YF17D/SIV
viruses could therefore be evaluated for immunogenicity and
safety in the rhesus monkey model. Accordingly, we demonstrated
that the recombinant YF17D/SIV Gag45–269 virus elicited SIV-
speciﬁc CD8þ T cell responses in the Indian rhesus macaques
after immunization (Bonaldo et al., 2010).
The second criterion for the rational design of the recombinant
virus was the physical chemical properties of this SIV Gag45–269
antigen. We also investigated whether the insert encoded any
transmembrane domains and whether it was hydrophobic. Both
characteristics might be deleterious to the correct topology and
processing of the downstream YF polyprotein precursor. The
selected SIV Gag45–269 expression cassette encoded 308 amino
acids, which included 10 residues from the N-terminus of the YF
17D virus NS1 protein (YF genome position from 2453 to 2482)
fused at its 50 terminal (Fig. 1A). At the C-terminal, the Gag45–269
cassette contains the motif KESSIG (YF genomic position from 2145
to 2164) followed by the truncated stem anchor domain of dengue
4 (DENV4) virus E protein containing two transmembrane helix
motifs called TM1 and TM2 (DENV4 genome positions 2226–2423;
GenBank GU289913) (Fig. 1A). Both transmembrane domains
could be predicted by the TMHMM software, speciﬁc for trans-
membrane helices in proteins (Fig. 1B). The presence of these
transmembrane motifs in the recombinant protein promotes its
anchoring in the ER membrane, facing the ER lumen (Bonaldo
et al., 2007). Additionally with the ProtParam Tool, we also
determined various physicochemical properties, such as the
expected molecular weight of 33.7 kDa and its hydrophilic char-
acter based on its Grand average of hydropathicity (GRAVY's
index) of – 0.138 (Supplementary Table 1). The hydrophilicity of
the foreign protein is probably an important property of the
recombinant protein, since it should be soluble and exposed in
the lumen of ER thereby not disturbing the arrangement of the
ﬂanking viral E and NS1 proteins.
Finally, the selected sequence was codon-optimized, based on
YF virus codon usage frequency. The synthetic gene was cloned
into YF genomic cDNA, which in turn was submitted to in vitro
transcription. Following Vero cell transfection with RNA, we
recovered the recombinant YF virus, identiﬁed as YF17D/SIV
Gag45–269 virus and re-infected Vero cell monolayers generating
a second passage viral stock, called P2, with a viral titer of
6.2 log10 PFU/ml.
The recombinant YF17D/SIV Gag45–269 virus is genetically
unstable
Genetic stability is one of the most important properties of a
recombinant live attenuated virus for a vaccine candidate. We,
therefore, genetically characterized the recombinant YF17D/SIV
Gag45–269 virus by sequencing the whole genome to conﬁrm the
expected nucleotide sequence of this virus as well as the integrity
of the heterologous cassette under successive passages in Vero
cells. We did not detect any point mutations in the second passage
virus samples (P2). However, by analyzing the size of the RT-PCR
amplicons containing the heterologous insertion, we observed a
reduction of the cassette size after the ﬁfth Vero cell serial passage
(Supplementary Fig. 1B). At the twentieth continuous cell passage,
most of the amplicons contained only recombinant Gag sequence
of the ﬁrst 27 nucleotides at the 50end and the last 178 nucleotides
of the gag45–269 gene. We reasoned that the particular region from
nucleotide 57 through 528 of the expression cassette might be
deleterious to the virus, and therefore, recombinant YF 17D viruses
with smaller foreign inserts were positively selected.
With the aim of understanding the nature of this constraint, we
compared the recombinant YF17D/SIV Gag45–269 virus to six other
Fig. 1. Schematic diagram of the YF17D SIVmac239 Gag45–269 expression cassette.
(A) Gag45–269 recombinant cassette fused at its 50 and 30 termini to YF motifs. The
N-terminus of NS1 is shown in red. The C-terminus is made up of different
components including the motif KESSIG (brown) and the truncated stem anchor
domains of Dengue 4 virus E protein, the putative stem H2 motif (green) followed
by the transmembrane domains T1 and T2 (blue). (B) Prediction plot of transmem-
brane helices in the Gag45–269 cassette using the TMHMM Programm. The sequence
was positioned inside or outside of endoplasmic reticulum (ER) based on the
absence of transmembrane helices and the expected viral polyprotein topology.
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recombinant YF 17D viruses expressing SIV Gag regions that were
41–166 amino acid residues long (Supplementary Table 2). By
comparing the genetic stability based on the amplicon proﬁles of
the complete set of YF17D/SIV Gag viruses, we observed that
the most unstable viruses were those expressing Gag45–269 and
Gag76–123 regions (Fig. 2). These YF17D/SIV Gag45–269 and YF17D/
SIV Gag76–123 viruses also displayed the lowest growth rates in
Vero cells (Supplementary Fig. 2). Interestingly, these unstable
viruses originally carried part of an Internal Ribosomal Entry Site
(IRES) domain present in the gag gene sequence that was partially
deleted upon serial passage.
Overcoming genetic instability of the gag gene expressed by the
recombinant YF 17D virus
The primate lentivirus gag coding region assumes a stable
secondary structure and carries one or several IRES domains that
are involved in recruiting the initiation complexes on several
initiation codons (Buck et al., 2001; Herbreteau et al., 2005;
Nicholson et al., 2006; Weill et al., 2010). In the SIVmac251
genomic RNA, the gag gene exhibits three initiation AUG codons
and eight intra-molecular base-pairing interactions, P1–P8. Nota-
bly, both gag 45–269 and gag 76–123 gene fragments bear the
pairings P5, P6 and P7, including the translation initiation AUG
codon present in P7 (Fig. 3A). So, given that the YF17D/SIV Gag45–
269 and YF17D/SIV Gag76–123 viruses are very unstable, we antici-
pated that these structural and functional IRES motifs might cause
a deleterious effect on YF viral ﬁtness disturbing ﬂaviviral transla-
tional or replicative processes during cell infection. Accordingly,
the creation of bicistronic ﬂaviviruses by inserting sequences
corresponding to IRES followed by reporter genes at the 30 UTR
of viral genome generated very unstable viruses leading to a
complete deletion of the heterologous IRES-bearing region after
few rounds of viral infection cycles (Deas et al., 2005; Pierson
et al., 2005; Zou et al., 2011).Therefore, we deduced that mutations
disrupting these elements (Fig. 3B and C) might improve the
genetic stability of the recombinant YF 17D viruses expressing this
Gag region.
For this purpose, we selected motifs involved in intra-strand
base pairing of stem loop regions of the P6 and P7 elements which
corresponds to one of the translation initiation regions based on
the secondary structure model described by Weill et al. (2010) for
the SIVmac251 gag 50 terminal region. In the P6 pairing region,
CACC forms a stem with GGUG corresponding to the SIV gag gene
position from 319 to 322 and 327 to 330, respectively (GenBank
AY588946). Despite the fact that the original YF17D/SIV Gag45–269
virus bears the CAUC motif instead of CACC, due to the codon
optimization synthesis of the gag 45–269 minigene sequence, it is
well known that uracil and guanine can form a single hydrogen
bond base pair in this kind of secondary RNA structure. Thus,
codon optimization at this site might not interfere with pair
formation in P6. To disrupt the pairing at P6, we modiﬁed the
GGUGGU sequence present in the recombinant YF17D/SIV Gag45–
269 virus (SIV gag gene position from 324 to 330; GenBank
AY588946) to AGUAGUA, without altering any amino acid in the
Gag protein fragment. In a second round of mutations, the AUGCC
sequence of the P7 motif was mutated to AUCGG (SIV gag gene
position from 352 to 357). These mutations led to two amino acid
Fig. 2. Viral genetic stability studies performed in seven recombinant YF 17D viruses expressing different Gag fragments. (A) Organization of SIV gag gene coding Matrix (M),
Capsid (C), Nucleocapsid (NC) proteins and the carboxy-terminal domain P6 as well as the spacer regions P1 and P2 (GenBank AY588946). (B) Electrophoretic analysis of
amplicons containing the insertion region obtained by RT-PCR of viral RNA extracted from supernatant of cultures after serial passages in Vero cells. Numbers of passages are
indicated above the ﬁgures. Gray arrows indicate the size of amplicons for viruses without insertion. Black arrows indicate the expected amplicon size for each recombinant
virus containing the complete insertion. The corresponding Gag fragment that is expressed by each recombinant YF virus is speciﬁed above the electrophoretic proﬁle.
(C) Expected amplicon sizes for each recombinant virus.
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modiﬁcations, in the ﬁrst codon, methionine to isoleucine (Gag
position 118) and in the second, proline to glycine (Gag position
119). Nevertheless, both cassettes retained the same physicochem-
ical properties, indicating that most probably they would not
interfere with structural characteristics (Supplementary Table 1).
Furthermore, the amino acid changes did not disrupt any of the
well-characterized SIVmac239 CD8þ and CD4þ T cell epitopes
recognized by the immune system of rhesus monkeys and present
in the Gag 45–269 fragment (Loffredo et al., 2007) (Supplementary
Table 3; Allen et al., 1998, 2001; Loffredo et al., 2004; Giraldo-Vela
et al., 2008). The recovered new virus carrying all these mutations
was viable and was designated YF17D/SIV GagΔIRES.
Genetic stability and growth properties of the YF17D/SIV
Gag45–269 and YF17D/SIV GagΔIRES viruses
In order to access the genetic stability of the new YF17D/SIV
GagΔIRES virus, we analyzed amplicons containing the insertion
region from viral RNA samples of two independent experiments
up to twenty serial passages in Vero cells. In all samples the
complete amplicon size of about 1.6 kb was detected without any
sign of continuous deletions in the heterologous cassette up to
twenty serial passages (Fig. 4A). The gain in genetic stability was
further conﬁrmed by sequencing the complete YF17D/SIV Gag-
ΔIRES genome from the 20th serial passage samples. We detected
neither any point mutation in the heterologous gene nor in the YF
genome, indicating that this new recombinant virus is stable.
Despite the increase in genetic stability, the proliferation
capability of the YF17D/SIV GagΔIRES virus in Vero cells did not
improve when compared to the original YF17D/SIV Gag45–269 virus
(Fig. 4B). Both recombinant viruses demonstrated lower prolifera-
tion rates in comparison with the YF 17D control viruses. This is
not surprising, since the insertion of heterologous sequences
into the YF genome, in general, led to decreased yields and
over attenuation (Bonaldo et al., 2005, 2007; Nogueira et al.,
2013). The reduction in yields can be best witnessed at 72 h
post-infection, when the control YF 17DD and YF17D/G1/2T3
viruses peaked with titers of 7.270.7 log10 PFU/ml and 7.97
0.5 log10 PFU/ml, respectively, whereas the recombinant YF17D/
SIV Gag45–269 exhibited a titer of 6.870.2 log10 PFU/ml and YF17D/
SIV GagΔIRES of 6.970.3 log10 PFU/ml.
The only statistically signiﬁcant difference in viral growth
(t-test; P¼0.0003) between the mutated YF17D/SIV GagΔIRES
(6.470.1 log10 PFU/ml) and the original YF17D/SIV Gag45–269
(5.870.1 log10 PFU/ml) viruses was detected at 48 h post-infection.
Expression of YF 17D and Gag proteins in infected Vero cells
When we performed a comparative immunoﬂuorescence assay
with a monoclonal antibody against the SIV Capsid p27 protein,
the recombinant Gag labeling was mainly localized in the
Fig. 3. Secondary structure model of the SIVmac239 50end of gag coding region, accordingly the model described by Weill et al., (2010). (A) The conserved structural
elements forming pairings are designated P1 through P8. The three AUG in frame, initiation codons yielding three isoforms of the Gag, are indicated by red zones.
Highlighted in a green box are indicated the elements P6 and P7 that were mutated in this work. The corresponding 50end of gag 45–269 and gag 76–123 minigenes are
indicated by green arrows and boxes. (B) Schematic drawing of the secondary structure of P6 and P7 RNA elements showing the nucleotides involved in pairing (green) as
well as the AUG initiation code location (red) as illustrated by the VARNA program (Darty et al., 2009). (C) Alignment of SIVmac239 gag sequence containing the P6 and P7
elements with the corresponding sequence of SIVmac251 gag (GenBank AY588946) that was used to establish the structural model described elsewhere (Weill et al., 2010).
(D) Alignment of the same gag regions present in YF17D/SIV Gag45–269 and the mutated version virus YF17D/SIV GagΔIRES. The mutated nucleotides in YF infectious clone
are shown in red. Nucleotide differences between the original SIV virus and recombinant YF17D/SIV viruses due to codon optimization are indicated in blue.
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perinuclear region of the cells, (Fig. 5A and B) as we expected. This
suggested that the recombinant protein was associated with the
ER compartment, as previously described for other recombinant
viruses, bearing insertions at the E/NS1 site (Bonaldo et al., 2007;
Nogueira et al., 2013; Trindade et al., 2012). Indeed, recent studies
have revealed that ER maintenance signals are present in the
ﬂaviviral E protein and that the length and some non-hydrophobic
residues existing in the two transmembrane domains are critical
for ER retention (Ciczora et al., 2010; Hsieh et al., 2010). Consider-
ing that the recombinant Gag45–269 is a chimeric protein that
Fig. 4. Viral genetic stability and proliferation studies of the new recombinant
YF17D/SIV GagΔIRES virus. (A) Electrophoretic analysis of amplicons containing the
insertion region obtained by RT-PCR of viral RNA extracted from supernatant of
cultures after serial passages in Vero cells. Numbers of passages are indicated above
the ﬁgure. On the right, a black arrow indicates the size of the amplicon containing
the complete heterologous expression cassette. On the left, the gray arrow points to
the position of the YF 17D vaccine amplicon that does not contain any insertion.
(B) Viral growth curves in Vero cells. Cells were infected with either the control YF
17DD (vaccine virus strain) and YF17D/G1/2T3 (parental clone) viruses or the
recombinant YF17D/SIV Gag45–269 or YF17D/SIV GagΔIRES viruses at MOI of 0.02.
Each time point represents the average titer obtained from three independent
experiments with the respective standard deviations.
Fig. 5. Studies of the expression of the recombinant SIV Gag45–269 protein by the
recombinant YF/SIV Gag45–269 viruses. Vero cells were viral infected with MOI of
0.1 and after 48 h post-infection, cells were processed and stained with antibodies.
(A) Immunoﬂuorescence for intracellular detection of YF antigens in non-infected
Vero cells monolayers (Mock) or cells infected with the YF 17D vaccine virus, the
recombinant YF17D/SIV Gag45–269 virus and YF17D/SIV GagΔIRES virus.
(B) Intracellular detection of Gag antigen in Vero cells non-infected monolayers
(Mock) or cells infected with YF 17D vaccine virus, the recombinant YF17D/SIV
Gag45–269 and YF17D/SIV GagΔIRES viruses. (C) Western blotting analysis for
detection of YF proteins in lysates of Vero cells under denaturing conditions.
Lanes: (1) Non-infected Vero cells lysates; (2) Lysates of Vero cells infected with YF
17DD virus; (3) YF17D/SIV Gag45–269 virus; (4) YF17D/SIV GagΔIRES virus. Mole-
cular weight markers are indicated on the right side of the membrane.
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carries both transmembrane domains in its C-terminal, and con-
sequently their retention motifs, the ER location is conceivable.
In a second set of experiments we characterized the viral
protein expression in infected Vero cell monolayers with Western
Blotting analysis to establish if the presence of these secondary
structured elements could interfere with the synthesis of YF
proteins (Fig. 5C). Because of the presence of IRES elements
mentioned above that could act as a second point of recruitment
of factors involved in translation, the synthesis of YF proteins
could be altered. However, the relative intensity of YF protein
bands corresponding to prM, which is translated from the YF RNA
50 end and non-structural proteins (NS1 and NS3) located down-
stream of the secondary-structured gag IRES elements, did not
differ between the two recombinant viruses, as evidenced when
the two gag minigene-containing viruses and the original YF 17D
vaccine virus are compared. These data suggested that there were
no differences in the translation of the YF genome in terms of the
location of YF genes regarding the gag gene. As a result, we
hypothesized that the deleterious effect associated with the
existence of part of a lentiviral gag IRES domain could be due to
the interaction of the IRES sequence motifs with YF virus RNA
folding sequence elements disrupting the original folding (Friebe
and Harris, 2010; Gebhard et al., 2011). Alternatively the IRES
folding may simply be a signal for the viral polymerase to jump
over upon RNA replication, leading to a deleterious effect in the
recombinant virus genome.
Immunogenicity of recombinant YF 17D viruses in mice
In the next step of this work, we determined if the genetic
modiﬁcations of the YF17D/SIV GagΔIRES virus did not impair its
ability to promote a proper antibody and cellular immune response
against the YF 17D virus and the SIV Gag45–269 foreign antigen.
Therefore, BALB/c mice were immunized subcutaneously with two
doses of recombinant virus as well as the YF 17DD vaccine counterpart
as a positive control and diluent medium as a negative control (mock).
In the ﬁrst study, we evaluated the ability of the recombinant YF 17D
viruses to elicit YF virus neutralizing antibodies (Table 1). Both
recombinant viruses induced YF neutralizing antibodies in compar-
ison with the mock immunized group (Po0.0001), but the neutraliz-
ing antibody titers of the recombinant viruses (YF17D/SIV Gag45–269 –
GMT 3076 and YF17D/SIV GagΔIRES – GMT 30714) were signiﬁ-
cantly lower than those for YF 17DD-immunized mice (GMT 182749;
Table 1). This suggested that there was a decrease in immunogenicity
induced by the recombinant YF virus, consistent with our previous
results with other recombinant viruses (Bonaldo et al., 2007). This, in
part, may be due to a reduction in viral ﬁtness, as shown in the
growth curves of the recombinant viruses which exhibited a decrease
of around 1 log10 PFU/ml at the peak of replication, when compared to
the vaccine counterpart YF 17DD. This might lead to limited viral
antigen production due to lower infectiousness to the mammalian
host. Genetic mutations, resulting from insertion of foreign sequences,
could alter viral attenuation and viral viability leading to reduced
immunogenicity.
In a second study, we evaluated the cellular immune response
against YF and Gag antigens by analyzing IFN-γ production by mouse
splenocytes (Fig. 6) ﬁfteen days after the second dose. With regard to
YF immune response, there was a signiﬁcant number of IFN-γ spot-
forming cells (SFC) against YF in all virus immunized mouse groups in
relation to the mock-immunized group. Indeed, the differences in the
number of IFN-γ secreting splenocytes among the three virus groups
were not signiﬁcant, with values of 122721 SFC for YF 17DD,115735
SFC for YF17D/SIV Gag45–269 and 139730 SFC for YF17D/SIV Gag-
ΔIRES viruses (Fig. 6A). We, therefore, concluded that YF 17D
recombinant viruses expressing Gag are equally immunogenic to the
commercial YF 17D vaccine virus with regard to their capacity to elicit
speciﬁc T cells against the YF virus.
Induction of Gag-speciﬁc IFN-γ secreting murine splenocytes was
equivalent among the two recombinant YF17D/SIV Gag45–269 and
YF17D/SIV GagΔIRES viruses (Fig. 6B). These responses were sig-
niﬁcantly higher in groups immunized with recombinant viruses in
comparison to the groups immunized with the medium (mock) or YF
17DD virus (Kruskall Wallis test with Dunn's post-test; Pr0.05)
(Fig. 6B). In contrast the magnitude of cellular responses elicited by
the recombinant viruses was not signiﬁcantly different. Interestingly,
the mutations introduced in the gag gene did not change the cellular
Table 1
Immunogenicity of the recombinant YF 17D viruses expressing Gag45–269 in BALB/c
mice: titers of YF virus neutralizing antibodies after 30 days of the last dose.
Immunogen Animals (n) % Sero-
conversion
to YF virus
PRNT50a
GMT7SDb Titer range
YF17DD 11 100 182789 27–1080
YF17D/SIV Gag45–269 13 90 3176 14–84
YF17D/SIV
GagΔIRES
11 100 30714 11–171
199 Earle's medium 10 0 o10 o10
a Values indicate the reciprocal of the dilution yielding 50% plaque reduction.
b Differences in the titers of neutralizing antibodies were statistically signiﬁ-
cant between 17DD immunized animals and YF17D/SIV Gag45–269 immunized
animals (po0.05) as well as YF17D/SIV GagΔIRES virus (Po 0.001). Kruskal–
Wallis with Dunn's post-test.
Fig. 6. ELISpot analysis of the induction of IFN-γ producing splenocytes after 14
days of mouse immunization. Groups of 5 mice were immunized twice with
medium (mock), YF17 DD vaccine and the recombinant YF17D/SIV Gag45–269 or
YF17D/SIV GagΔIRES viruses. Spleen cells stimulated with heat-killed YF 17D virus
(A) or with peptide pools corresponding to the inserted part of SIV-Gag protein.
Data are representative of two independent experiments.
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immune response against Gag. For further insight in this matter, we
performed an analysis adopting the IEDB Analysis Resource (http://
tools.immuneepitope.org/). We utilized amino acid sequences from
both recombinant Gag viruses to predict epitope binding to MHC
class I and II molecules expressed by BALB/c mice (Supplementary
Table 4). The predicted epitopes obtained for BALB/c mice were
exactly the same for both recombinant viruses and correspond to
Gag peptide pools B and E employed in our ELISpot assays.
Importantly, these epitopes do not overlap with the mutagenized
amino acid positions that are localized in peptide pool C.
Aiming to better characterize the proﬁle of the cellular immune
responses induced by YF 17D virus vaccination, we analyzed produc-
tion of IFN-γ and IL-2 by splenocytes stimulated with whole inacti-
vated YF 17D virus or a peptide pool spanning the Gag45–269 protein.
This inactivated virus is constituted by YFV structural proteins, which
have already been described as having epitopes recognized by MHCs
class I and II of BALB/c mice (Maciel et al., 2008).
In this investigation, we initially gated the lymphocytes from
splenocyte samples according to cell morphology (FSC SSC) and
to the expression of CD4 or CD8 markers (Supplementary Fig. 3).
As can be seen in Fig. 7 (panels A and C), we detected double
positive IL-2þ IFN-γþ lymphocytes in all mouse groups that were
immunized with the recombinant viruses and the control YF 17D
virus when stimulated by the inactivated YF 17D virus. This
phenotype was mainly associated with the CD4þ T cell subset,
which was described to be an important feature of immunization
with the YF vector (Franco et al., 2010; Neves et al., 2010). The
same proﬁle was apparent in CD4þ and CD8þ T cells stimulated
with a Gag peptide pool (Fig. 7B and D) in splenocytes from groups
immunized with either of the recombinant YF 17D viruses.
Interestingly, despite the genetic modiﬁcations performed in the
recombinant gag gene that promoted a substantial increment in viral
genetic stability, these changes did not lead to an increase of viral
immunogenicity and proliferation rates. One of the possible explana-
tions could be that the accumulation of the recombinant Gag proteins
inside the ER, perhaps forming oligomers due to the presence of part
of the SIV capsid protein, could trigger and accelerate cellular stress,
leading to a signaling cascade and apoptosis (Todd et al., 2008). In fact,
Vero cells infected with the recombinant YF17D/SIV Gag45–269 viruses
appeared to have accelerated death when compared to the parental
virus due to extensive cell mortality early in infection (data not
shown). It is known that dendritic cells (DC) engulf apoptotic bodies
and present the antigens to CD4þ T cells (Green et al., 2009), and the
YF 17D virus infects mouse DC as well as human DCs (Barba-Spaeth
et al., 2005; Castellino and Germain, 2006; Palmer et al., 2007; Querec
et al., 2006). We, therefore, reasoned that in vivo death of infected DCs
activates bystander DCs, which might present the YF and Gag epitopes
to CD4þ T cells leading to robust CD8 responses, a hallmark of
immunization with the YF 17D virus (Castellino and Germain, 2006;
Miller et al., 2005). In this regard, it is noteworthy that this same
recombinant virus elicited CD8þ Tcell responses against Gag epitopes
in vaccinated rhesus monkeys (Bonaldo et al., 2010).
Conclusions and perspectives
In this work we were successful in improving the genetic
stability of YF 17D recombinant viruses expressing the SIVmac239
Gag45–269 protein fragment by mutating secondary structures
present in this gene segment. Importantly, these modiﬁcations of
the recombinant YF17D/SIV Gag45–269 virus were not accompanied
by impairments in rates of viral growth or immunogenicity in a
mouse model. Accordingly, we are extending these analyses to
other YF 17D viruses expressing lentiviral Gag, Nef and Vif
fragments. This should provide a better evaluation of immunolo-
gical properties of the recombinant YF 17D viruses in the
development of new HIV vaccine candidates. Obviously, this
approach does not apply to other IRES-free sequences and indeed
it strongly suggests that to solve the problem of genetic instability
of YF 17D recombinant viruses bearing insertions at E-NS1, we
should take into account the functional and structural character-
istics of each foreign sequence to be expressed.
Materials and methods
Cell culture
Vero cells (ATCC) derived from the kidney of an African green
monkey were maintained in Earle's 199 complete medium sup-
plemented with 5% fetal bovine serum (FBS).
Generation of recombinant YF 17D/Gag viruses
In the recovery of the YF 17D virus from cDNA, the parental YF17D/
G1/2-T3 vector virus and the recombinant YF17D/SIV Gag45–269 virus
were constructed employing the two plasmid- infectious clone
technology (Rice et al., 1989). In this approach, the entire YF genomic
cDNA is split in the pG1/2 and pT3, which are derivatives of the
original pYF5030IV and pYFM5.2 plasmids (Rice et al., 1989). Plasmid
pG1/2, with 6905 bp contains the ﬁrst 2271 nucleotides fused to the
2588 nucleotides of the 30terminal of the YF genome. This plasmid
carries the following mutations at the following genomic positions:
1140, 1436/1437, 8808 and 9605 (all displaying amino acid changes)
and 10,454 and 10,722, rendering it 17DD-like (GenBank accession
number: U17066.1). Plasmid pT3 is a derivative of pYFM5.2 with 9939
bp and contains the central portion of the YF genome extended to the
SalI site at position 8060 as compared to plasmid pYFM5.2. The T3
plasmid also includes mutations at nucleotides 2356, 2602, 2677,
2681, 8656 (BstE II site) and 8808 (Display amino acid changes), as
compared to YF 17D-204 (GenBank accession number: X15062.1). The
sequences of the inserts were codon-optimized and synthesized by
Geneart GmbH (Regensburg, Germany) and then cloned into the pT3
backbone with the EagI/NarI sites. The viral cDNA template was
created as well as recombinant viruses obtained as described else-
where (Bonaldo et al., 2007; Nogueira et al., 2013).
Genetic stability studies and nucleotide sequencing
To access the genetic stability of recombinant YF 17D viruses, two
independent serial passage experiments were performed for each
recombinant virus. Recombinant viruses were submitted
to either ﬁfteen or twenty consecutive passages in Vero cells at a
MOI of 0.02. RNA samples of each passage were obtained and
sequenced as described elsewhere (Bonaldo et al., 2007). Brieﬂy, viral
RNA was extracted from culture supernatants with the QIAamp Viral
RNA kit (Qiagen) and ampliﬁed by RT-PCR the viral E-NS1 genomic
region with a negative strand YF-speciﬁc synthetic oligonucleotide
(genome position 2772–2795) together with the positive YF-speciﬁc
primer (genome position 2122–2145). To obtain the sequence of the
entire YF genome, a total of 12 RT/PCR products were synthesized
encompassing nucleotides 1–1202, 854–2093, 1842–3206, 2871–
4261, 3868–5202, 4831–6215, 5873–7195, 6846–8252, 7854–9228,
8850–10195, 9879–10326 and 10230–10862. RT-PCR was carried
out with Superscript III (Invitrogen) and GoTaq Green Master Mix
(Promega) as recommended by producers. To sequence serial
passage samples from the YF17D/SIV Gag45–269 virus that showed
a mixed proﬁle of amplicons in the insert region, they were cloned
in the pGEM T-Easy plasmid (Promega) and the primers M13F and
M13R used to determine the amplicon sequence. All the samples
were sequenced by the Sanger sequencing method as previously
described (Bonaldo et al., 2007).
M.G.V.d. Santana et al. / Virology 452-453 (2014) 202–211208
Immunoﬂuorescence microscopy
The immunoﬂuorescence analyses were performed as described
previously (Bonaldo et al., 2007). The primary mouse α-p27 antibody
FITC conjugated (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: SIVmac p27 Hybridoma-55-2F12- from
Dr. Niels Pedersen) was diluted 1:50 and the antibody mouse α-E
protein (clone 2D12, Bio- Manguinhos) was diluted 1:200. For E
protein staining, a secondary antibody was used in the analysis diluted
1:400 (Alexa Fluor 546 goat anti-mouse IgG-Invitrogen). Both
preparations were treated with SlowFade-Gold antifade reagent with
DAPI (Invitrogen, Grand Island, NY) and Fluorescence Microscopy was
performed with the Olympus IX51 Inverted Microscope.
Western blotting
After 48 h of incubation, Vero cell monolayers infected at MOI
of 0.1 were washed twice with PBS and resuspended in lysis buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.25% Triton
X-100, 25 mg/ml PMSF, 50 mM leupeptin) at a concentration of
Fig. 7. Functional proﬁle of CD4þ and CD8þ T cell responses in mice immunized with YF 17D and recombinant YF 17D viruses. We carried out multi-parameter ICS at day 14
after the second immunization to determine the ability of YF 17D and Gag speciﬁc splenocytes to secrete IFN-у and/ or IL-2. The antigen stimuli in this assay consisted of
whole inactivated YF 17DD virus or pools of SIVmac239 Gag peptides spanning the fragment Gag 45–269. Bar graphs indicate the average total frequency of IFN-уþ (black),
IL-2þ (white) or IFN-уþ IL-2þ (gray). (A) CD4þ T cells stimulated with YF 17DD virus, (B) CD4þ T cells stimulated with peptide pools of Gag, (C) CD8þ T cells stimulated
with YF 17DD virus, (D) CD8þ T cells stimulated with peptide pools of Gag. The data were obtained from two independent experiments.
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approximately 5106 cells/ml, considering the initial number of
seeded cells before viral infection. Lysates were vortexed for 1 min
and submitted to centrifugation at 12,000g. The supernatants were
collected and the concentration of protein determined by Qubit
Protein Assay Kit (Life Technologies). The equivalent volume
containing 20 ug of protein was mixed to the ﬁnal 1 Laemmli
buffer, supplemented with 5% of 2-mercaptoethanol. Samples
were heated for 5 min at 95 1C. Proteins in cellular extracts were
then resolved by SDS-PAGE and subsequently transferred to PVDF
membranes. Nonspeciﬁc sites on membranes were blocked with
5% nonfat milk in PBS-T (PBS pH 7.4, 0.1% Tween 20). Primary
antibodies from mouse YF 17D polyclonal hyperimmune mouse
ascitic ﬂuid were diluted 1:2000 in 1% nonfat milk/PBST prior to
incubation with membranes for 2 h at room temperature. The
membranes were washed with PBST and incubated with second-
ary (goat α-rabbit HRP-conjugated, Amersham Biosciences) anti-
bodies diluted 1:5000 in 1% nonfat milk/PBST for at least 1 h at
room temperature. Membranes were washed extensively with
PBST and then developed with enhanced chemiluminescence
(Amersham Biosciences) and autoradiography.
Animals and immunization protocols
Female BALB/c mice, 4–6 weeks old (CEMIB-UNICAMP, Campi-
nas, São Paulo), were used in the YF 17D immunization studies.
Groups of 5 mice were subcutaneously injected with two doses of
cell culture media alone or 100,000 PFU of YF17D/SIV Gag45–269,
YF17D/SIV GagΔIRES or YF 17DD viruses with an interval of 15
days. Animal work was conducted in accordance with approved
institutional animal ethics committee protocols (CEUA L-47/2011).
Plaque reduction neutralization test (PRNT)
Four weeks after the last immunization, mice were bled by
cardiac puncture. Serum sample treatment and YF neutralizing
antibody titration were carried out by a method previously
described (Bonaldo et al., 2007; Stefano et al., 1999). The values
of neutralizing antibody titers of each experimental group were
compared with the Kruskall Wallis test (GraphPad Prism 5.02
Program). The differences were considered signiﬁcant when
Po0.05.
Antigenic sources
The YF 17DD virus adopted as an antigen during immunologic
assays was obtained by cultivating the vaccine virus (MOI 1) in
VERO cells until the appearance of the cytopathic effect. The
infected-cell culture supernatant was clariﬁed by centrifugation
at 400 g for 15 min and aliquoted before storage at 80 1C. The
virus was titrated in triplicate. Inactivation was performed by
heating at 56 1C for 30 min. It has been already demonstrated that
wild-type yellow fever virus, dengue virus, West Nile virus and
hepatitis C virus (Fang et al., 2009; Song et al., 2010) are efﬁciently
inactivated by this heating cycle regime. Since the YF 17D virus
was titrated prior to heat inactivation an equivalent MOI of
10 PFU/cell was applied.
A set of 60 peptides of 15 amino acids overlapping by 11
(1511) and comprising the length between positions 41 and 291
of the SIVmac239 Gag protein, which encompass the entire Gag45–
269 fragment was obtained from the NIH AIDS reagent program.
The peptides were solubilized in DMSO and divided in pools of 10
peptides each, totaling 6 peptide pools called B, C, D, E, F and G,
that match to the following Gag sequence intervals, 41–91, 81–131,
121–171, 161–211, 201–251 and 241–291, respectively.
IFN-γ ELISpot assay
For the IFN-γ ELISpot assay, groups of 5 mice, in each experi-
ment, were immunized as described above. Fifteen days after the
second immunization, the mice were sacriﬁced and the spleens
removed. Splenocytes were isolated by standard methods as
previously described (Nogueira et al., 2013). The results are
presented after subtraction of the background and were compared
adopting the Kruskall Wallis test with Dunn's post-test (GraphPad
Prism 5.02 Program). The differences were considered signiﬁcant
when Po0.05.
Intracellular cytokine staining (ICS)
Splenocytes from immunized mice were also assayed by ICS for
interleukin 2 (IL-2) and IFN-γ. The cell suspensions, obtained as
described above, were suspended to a ﬁnal concentration of
approximately 107 cells/ml. All groups of harvested spleen cells
(1106 cells /tube) were stimulated for 18 h with (1) medium
alone, (2) whole heat-inactivated YF 17D virus, (3) pool of peptides
described above or (4) concanavalin A (2 μg/ml; Sigma, St. Louis,
MO) in the presence of 1 μg of anti-CD28 and anti-CD49d mono-
clonal antibodies/ml (BD PharMingen, San Diego, CA). Five hours
before the end of the incubation, 10 μg/ml of brefeldin A (Sigma,
St. Louis, MO) was added to each tube. Cells were then washed
(PBS 10% FCS) and stained for surface antigens with PerCP anti-
CD8 and Alexa 647 anti-CD4 mouse monoclonal antibodies (BD-
Biosciences PharMingen, San Diego, CA). The cells were washed
again, ﬁxed with paraformaldehyde 2%, permeabilized (PBS 10%
FCS 0,1% Saponin) and stained with monoclonal antibodies FITC
anti-IL-2 and PE anti-IFN-γ (BD-Biosciences PharMingen, San
Diego, CA) followed by multiparametric ﬂow cytometry on FACS-
calibur ﬂow cytometer using the CellQuest software (BD Bios-
ciences, San Jose, CA). The data were analyzed with FlowJo 7.6.5 for
Windows software (Tree Star, Ashland, OR).
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